Melasma, Melanocytes and Working With the Skin
Featured in Mocha Beauty Year 19, Issue 4.
Most melasma treatment plans focus on suppressing pigment, but Clare Lamberth, Larimedical Business Development Manager at The Australian Dermal & Laser Institute (TADLI), argues the real issue lies deeper: melasma is a chronic inflammatory and vascular condition, not simply a pigment problem. Aggressive peeling can trigger the "melasma boomerang", short-term brightening followed by rebound pigmentation and barrier damage.
Larimedical by Larimide's biomimetic peel range takes a different approach, working with the skin's own repair pathways rather than forcing shedding through acid-driven trauma. Clinics using this protocol are reporting more stable, longer-lasting clearance, including in higher Fitzpatrick skin types where PIH risk has historically been a barrier to pigmentation treatment.
Comments